- BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study
- The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”)
- The technology is exclusively licensed from the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen
- CEO Amir Reichman is scheduled to present in person at the Biotech Showcase (San Francisco – January 9th during JPM Healthcare conference week) and the BIO CEO & Investor Conference (New York – February 6th)
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products used primarily for the treatment of infectious and autoimmune diseases, recently released key financials for the quarter ending September 30, 2022, and highlighted important business updates (https://ibn.fm/NlQaQ).
The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies to address diseases underserved by current treatments and with large, growing markets, including infectious and autoimmune diseases such as COVID-19, asthma, psoriasis, psoriatic arthritis and macular degeneration. BiondVax is working in collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPI-NAT) and the University Medical Center Göttingen (“UMG”), both in Germany.
The global infectious disease therapeutics market was valued at $115 billion in 2021. It is expected to grow at a CAGR of 4.23%, resulting in an estimated value of $167 billion by 2030. Market growth can be attributed to the rising prevalence of infectious diseases worldwide, brought into focus with the recent COVID-19 pandemic (https://ibn.fm/KUL1X). Likewise, the global autoimmune disease therapeutics market is expected to experience significant growth. Valued at $109.83 billion in 2017, the market is expected to grow at a CAGR of 4.2%, resulting in a value of $153.32 billion by 2025. The adoption of alternative treatments and the increase in the incidence of autoimmune diseases are driving factors for global growth (https://ibn.fm/4LQI1).
BiondVax reported that through its collaboration with MPG and UMG, its pipeline for NanoAb therapies is proceeding according to plan. BiondVax’s lead nanosized antibody (NanoAbs) candidate is being formulated as a convenient self‑administered, inhaled COVID-19 therapy. In Germany, a preclinical proof-of-concept study of the COVID-19 NanoAb as an inhaled therapy in COVID-19-infected animals showed highly statistically significant results (p < 0.001), with the weight of the NanoAb-treated group of hamsters declining only 3.80% compared to the significant 12.01% weight loss of the control (placebo) group. This trial is expected to continue in January 2023 with testing the NanoAb at lower doses and as a prophylactic (preventative) medicine, followed by a first-in-human Phase 1/2a to be initiated during 2023. The next planned NanoAb to be tested will target IL-17 as drug candidates designed to address certain autoimmune diseases such as psoriasis.
Reported in New Israel Shekels (“NIS”), BiondVax’s financials ending September 30, 2022, showed cash and equivalents of NIS 29.4 million compared to NIS 54 million as of December 21, 2021.
The company had received a notice of non-compliance with NASDAQ listing rules regarding minimum Shareholders’ Equity and minimum share bid price. BiondVax quickly satisfied the requirements and has regained compliance with NASDAQ. In addition to restructuring debt repayment, the company executed a ratio change between its ordinary shares and its American Depository Shares (“ADS”) traded on NASDAQ.
In late December, the company raised an additional $7.3 net in a public underwritten offering. With funding in place to continue pipeline development, BiondVax intends to initiate a first-in-human Phase 1/2a clinical trial by the end of 2023 of the inhaled COVID-19 NanoAb therapy, and also to work to expand its pipeline by adding at least one other NanoAb, possibly one to treat psoriasis.
After the great interest generated during the company’s recent presentations at the HCW 24th Annual Global Investment Conference, LD Micro Main Event XV, and RAFT 14, BiondVax’s CEO Amir Reichman has scheduled to present in person at the Biotech Showcase Conference. Biotech showcase is held in parallel with the annual JPM Healthcare Conference in San Francisco on January 9-11, 2023. He will also participate at the BIO CEO & Investor Conference in New York on February 6-9, 2023. Investors and industry leaders interested in meeting with Mr. Reichman can contact BiondVax directly to schedule.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all
